OCUL
Price
$7.06
Change
-$0.39 (-5.23%)
Updated
May 9 closing price
Capitalization
1.12B
93 days until earnings call
VRDN
Price
$12.39
Change
-$0.39 (-3.05%)
Updated
May 9 closing price
Capitalization
1.01B
88 days until earnings call
Ad is loading...

OCUL vs VRDN

Header iconOCUL vs VRDN Comparison
Open Charts OCUL vs VRDNBanner chart's image
Ocular Therapeutix
Price$7.06
Change-$0.39 (-5.23%)
Volume$1.19M
Capitalization1.12B
Viridian Therapeutics
Price$12.39
Change-$0.39 (-3.05%)
Volume$655.73K
Capitalization1.01B
OCUL vs VRDN Comparison Chart
Loading...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
OCUL vs. VRDN commentary
May 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OCUL is a Hold and VRDN is a Hold.

Ad is loading...
COMPARISON
Comparison
May 11, 2025
Stock price -- (OCUL: $7.06 vs. VRDN: $12.39)
Brand notoriety: OCUL and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OCUL: 68% vs. VRDN: 72%
Market capitalization -- OCUL: $1.12B vs. VRDN: $1.01B
OCUL [@Biotechnology] is valued at $1.12B. VRDN’s [@Biotechnology] market capitalization is $1.01B. The market cap for tickers in the [@Biotechnology] industry ranges from $296.96B to $0. The average market capitalization across the [@Biotechnology] industry is $2.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OCUL’s FA Score shows that 0 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • OCUL’s FA Score: 0 green, 5 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, OCUL is a better buy in the long-term than VRDN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OCUL’s TA Score shows that 4 TA indicator(s) are bullish while VRDN’s TA Score has 4 bullish TA indicator(s).

  • OCUL’s TA Score: 4 bullish, 6 bearish.
  • VRDN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, VRDN is a better buy in the short-term than OCUL.

Price Growth

OCUL (@Biotechnology) experienced а -19.77% price change this week, while VRDN (@Biotechnology) price change was -9.03% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.25%. For the same industry, the average monthly price growth was +9.40%, and the average quarterly price growth was -13.49%.

Reported Earning Dates

OCUL is expected to report earnings on Aug 11, 2025.

VRDN is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (-6.25% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCUL($1.13B) has a higher market cap than VRDN($1.01B). OCUL YTD gains are higher at: -17.330 vs. VRDN (-35.368). OCUL has higher annual earnings (EBITDA): -176.14M vs. VRDN (-266.36M). VRDN has more cash in the bank: 718M vs. OCUL (392M). VRDN has less debt than OCUL: VRDN (21.1M) vs OCUL (75.8M). OCUL has higher revenues than VRDN: OCUL (63.7M) vs VRDN (302K).
OCULVRDNOCUL / VRDN
Capitalization1.13B1.01B111%
EBITDA-176.14M-266.36M66%
Gain YTD-17.330-35.36849%
P/E RatioN/AN/A-
Revenue63.7M302K21,093%
Total Cash392M718M55%
Total Debt75.8M21.1M359%
FUNDAMENTALS RATINGS
OCUL vs VRDN: Fundamental Ratings
OCUL
VRDN
OUTLOOK RATING
1..100
107
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
92
Overvalued
PROFIT vs RISK RATING
1..100
9084
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
4762
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OCUL's Valuation (53) in the Pharmaceuticals Other industry is somewhat better than the same rating for VRDN (92) in the Biotechnology industry. This means that OCUL’s stock grew somewhat faster than VRDN’s over the last 12 months.

VRDN's Profit vs Risk Rating (84) in the Biotechnology industry is in the same range as OCUL (90) in the Pharmaceuticals Other industry. This means that VRDN’s stock grew similarly to OCUL’s over the last 12 months.

VRDN's SMR Rating (98) in the Biotechnology industry is in the same range as OCUL (98) in the Pharmaceuticals Other industry. This means that VRDN’s stock grew similarly to OCUL’s over the last 12 months.

OCUL's Price Growth Rating (47) in the Pharmaceuticals Other industry is in the same range as VRDN (62) in the Biotechnology industry. This means that OCUL’s stock grew similarly to VRDN’s over the last 12 months.

OCUL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as VRDN (100) in the Biotechnology industry. This means that OCUL’s stock grew similarly to VRDN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
OCULVRDN
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 9 days ago
80%
Bullish Trend 3 days ago
80%
Declines
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 5 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA298.2613.44
+4.72%
Tesla
GME27.540.76
+2.84%
GameStop Corp
AAPL198.531.04
+0.53%
Apple
SPY564.34-0.72
-0.13%
SPDR® S&P 500® ETF
BTC.X102970.850000-270.609380
-0.26%
Bitcoin cryptocurrency

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with EYPT. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
-5.23%
EYPT - OCUL
56%
Loosely correlated
-4.75%
IMVT - OCUL
51%
Loosely correlated
-1.96%
XENE - OCUL
50%
Loosely correlated
-1.46%
BHVN - OCUL
50%
Loosely correlated
-0.05%
DNLI - OCUL
49%
Loosely correlated
-0.42%
More

VRDN and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with AURA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then AURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRDN
1D Price
Change %
VRDN100%
-3.05%
AURA - VRDN
50%
Loosely correlated
-9.83%
DNLI - VRDN
50%
Loosely correlated
-0.42%
BEAM - VRDN
46%
Loosely correlated
+0.93%
CCCC - VRDN
46%
Loosely correlated
-4.55%
OCUL - VRDN
46%
Loosely correlated
-5.23%
More